Point72 Asia (hong Kong) Ltd adds Boston Scientific Corporation (BSX) to its portfolio

Boston Scientific Corporation (BSX) : Point72 Asia (hong Kong) Ltd added new position in Boston Scientific Corporation during the most recent quarter end. The investment management firm now holds 47,941 shares of Boston Scientific Corporation which is valued at $1,145,310 , the company said in a statement filed on Aug 15, 2016 with the SEC.Boston Scientific Corporation makes up approximately 2.10% of Point72 Asia (hong Kong) Ltd’s portfolio.

Other Hedge Funds, Including , Two Sigma Advisers Lp added BSX to its portfolio by purchasing 49,457 company shares during the most recent quarter which is valued at $1,181,528. Boston Scientific Corporation makes up approx 0.01% of Two Sigma Advisers Lp’s portfolio.Raymond James Associates boosted its stake in BSX in the latest quarter, The investment management firm added 143,017 additional shares and now holds a total of 620,352 shares of Boston Scientific Corporation which is valued at $14,820,209. Boston Scientific Corporation makes up approx 0.04% of Raymond James Associates’s portfolio.Quantum Capital Management reduced its stake in BSX by selling 28,535 shares or 4.25% in the most recent quarter. The Hedge Fund company now holds 643,399 shares of BSX which is valued at $15,370,802. Boston Scientific Corporation makes up approx 2.08% of Quantum Capital Management’s portfolio.

Boston Scientific Corporation opened for trading at $24.07 and hit $24.35 on the upside on Thursday, eventually ending the session at $24.33, with a gain of 2.14% or 0.51 points. The heightened volatility saw the trading volume jump to 91,15,567 shares. Company has a market cap of $33,107 M.

On the company’s financial health, Boston Scientific Corporation reported $0.27 EPS for the quarter, based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus estimate of $0.27. The company had revenue of $2126.00 million for the quarter, compared to analysts expectations of $2044.88 million. The company’s revenue was up 15.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.22 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Boston Scientific Corporation was Upgraded by Argus to ” Buy” on Sep 1, 2016. Company shares were Reiterated by Wedbush on Jul 29, 2016 to “Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $23 .Company shares were Reiterated by Needham on Jul 29, 2016 to “Buy”, Firm has raised the Price Target to $ 28 from a previous price target of $26 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.